Compare Adaptive Biotechnologies Corp (ADPT) vs Baidu Inc (BIDU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Baidu Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.03 (market cap $4.04B), while Baidu Inc trades at $104.5 (market cap $36.18B). The key difference: Baidu Inc is far larger — about 9× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Baidu Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | BIDU | |
|---|---|---|
Market Cap | $4.04B | $36.18B |
Sector | Health | Media |
52-Week High | $25.45 | $162.52 |
52-Week Low | $12.30 | $86.76 |
Enterprise Value | $4.10B | $32.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Baidu (BIDU) trades at $103.7, down 5.3% in the last session, reflecting bearish technical signals and recent earnings volatility. The stock shows weak profitability with a net margin of 1.02% and elevated P/E of 78.19, though it trades below book value. Recent news highlights autonomous vehicle testing in London and an upcoming Q2 2026 earnings report on August 18, 2026 (PRNewsWire, 2026-07-31).
Outlook is mixed: strong analyst buy consensus (75.47%) and a $169.80 price target suggest upside, but declining revenue, negative cash flows, and China market risks pose headwinds. AI initiatives offer growth potential, but investors face execution and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Baidu Inc
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →
